Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide, marketed as Mounjaro, are the rock stars of the pharma market and are ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...

Bullish option flow detected in Eli Lilly (LLY) with 11,152 calls trading, 1.3x expected, and implied vol increasing almost 2 points to 39.19%.

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, ...